Physician profile
Sue E Myers
NPI 1083601280
$3,679.70
in general payments reported to CMS, 2019-2025
18 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $176 · 2021: $585 · 2022: $699 · 2023: $192 · 2024: $269 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $473.91 | 2022-2025 | Tryptyr, Hydrus Microstent, Voyager Dslt |
| Allergan, INC. | $356.31 | 2019-2022 | |
| Biotissue Holdings INC. | $355.32 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $274.71 | 2019-2024 | Tecnis Iol, Veritas Vision System |
| Sun Pharmaceutical Industries INC. | $274.60 | 2019-2023 | Cequa |
| Glaukos Corporation | $262.87 | 2021-2025 | Photrexa Viscous and Photrexa |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.74 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $248.45 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $223.56 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $212.58 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $117.18 | 2020 | |
| Novartis Pharmaceuticals Corporation | $104.66 | 2019-2023 | |
| Shire North American Group INC | $78.76 | 2019 | |
| Dompe US, INC. | $77.46 | 2024-2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $62.71 | 2019-2021 | |
| Oyster Point Pharma, INC. | $29.76 | 2022 | |
| Abbvie INC. | $27.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.